Marathon Asset Management signed a deal to acquire Kaléo for $310 million in cash as the firm boosts its healthcare-oriented investments.
Richmond, Virginia-based Kaléo is a privately held pharmaceutical company that serves patients at risk for anaphylaxis and other serious life-threatening conditions. The deal will offer liquidity for Kaléo shareholders upon closing in a series of cash payments through 2023.
“The sales trajectory of Kaléo has been impressive, and we view the company as a platform for growth,” said Dr. Evan Bedil, head of healthcare at Marathon. “We . . .
Unlock this article instantly, along with the rest of our premium content and daily, weekly and monthly newsletters. We offer pay-as-you-go monthly subscriptions and discounted annual subscriptions with additional benefits: access to Alternatives Watch Research articles and our Annual Investor Compendium.